$Arbutus Biopharma (ABUS.US)$$Barinthus Biotherapeutics (BRN...
$Arbutus Biopharma(ABUS.US$ $Barinthus Biotherapeutics(BRNS.US$ Arbutus Biopharma (ABUS) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' (BRNS) VTP-300 was generally safe and well-tolerated.
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
The company said there were no serious adverse events, grade 3 or 4 adverse events or discontinuations due to treatment with imdusiran and VTP-300. The data were presented at the European Association for the Study of the Liver Congress.
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
The company said there were no serious adverse events, grade 3 or 4 adverse events or discontinuations due to treatment with imdusiran and VTP-300. The data were presented at the European Association for the Study of the Liver Congress.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
